• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性骨髓瘤及伴有骨病变的实体癌中碱性磷酸酶(alp)水平:有差异吗?

Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?

作者信息

Annibali O, Petrucci M T, Santini D, Bongarzoni V, Russano M, Pisani F, Venditti O, Pantano F, Rago A, Siniscalchi A, Cerchiara E, Franceschini L, De Rosa L, Mariani M, Andriani S, Cudillo L, Garcia M, Cantonetti M, Mohamed S, Anaclerico B, Caravita T, Stocchi F, Cimino G, Gumenyuk S, Vozella F, Avvisati G

机构信息

Gruppo Mieloma Lazio, Italy.

Oncologia Medica, Università Campus Bio Medico di Roma, Italy.

出版信息

J Bone Oncol. 2020 Nov 18;26:100338. doi: 10.1016/j.jbo.2020.100338. eCollection 2021 Feb.

DOI:10.1016/j.jbo.2020.100338
PMID:33304804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7708946/
Abstract

INTRODUCTION

Bone involvement in Multiple Myeloma results from increased osteoclast formation and activity that occurs in proximity to myeloma cells. The role of Alkaline Phosphatse (ALP) in this process and the diagnostic significance of plasma levels in patients with MM are unclear.

AIM

To compare plasma ALP levels in patients with MM and solid cancers and metastatic lesions to the bone.

RESULTS

In this observational retrospective study we enrolled 901 patients were enrolled: 440 patients (49%) with Multiple Myeloma, 461 (51%) with solid cancers. All 901 patients had bone lesions. Among patients with Multiple Myeloma, ALP values were mainly in the range of normality than those observed in patients with solid cancers and bone lesions. This difference is independent of stage, number and type of bone lesions.

CONCLUSION

This study suggests that plasma ALP has a different clinical significance in MM than in other neoplasms and could be used as a discriminating marker in presence of bone lesions. In particular, lower or normal values, should suggest further investigations such as urinary and serum electrophoresis, associated with bone marrow aspirate in case of the presence of a monoclonal component, in order to confirm or exclude a MM diagnosis.

摘要

引言

多发性骨髓瘤中的骨受累是由于骨髓瘤细胞附近破骨细胞形成增加和活性增强所致。碱性磷酸酶(ALP)在此过程中的作用以及MM患者血浆水平的诊断意义尚不清楚。

目的

比较MM患者与实体癌及骨转移瘤患者的血浆ALP水平。

结果

在这项观察性回顾性研究中,我们纳入了901例患者:440例(49%)多发性骨髓瘤患者,461例(51%)实体癌患者。所有901例患者均有骨病变。在多发性骨髓瘤患者中,ALP值主要处于正常范围内,低于实体癌和骨病变患者。这种差异与骨病变的分期、数量和类型无关。

结论

本研究表明,血浆ALP在MM中的临床意义与其他肿瘤不同,可作为存在骨病变时的鉴别标志物。特别是,较低或正常的值应提示进一步检查,如尿液和血清电泳,若存在单克隆成分则结合骨髓穿刺,以确认或排除MM诊断。

相似文献

1
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?多发性骨髓瘤及伴有骨病变的实体癌中碱性磷酸酶(alp)水平:有差异吗?
J Bone Oncol. 2020 Nov 18;26:100338. doi: 10.1016/j.jbo.2020.100338. eCollection 2021 Feb.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
Serum Alkaline Phosphatase in Newly Diagnosed Genito-Urinary Cancers-Do We Need to Review the Guidelines?血清碱性磷酸酶在新诊断的泌尿生殖系统癌症中的应用-我们是否需要重新审视指南?
Gulf J Oncolog. 2022 Jan;1(38):24-30.
4
Biochemical markers for assessment of bone metastases in patients with breast cancer.用于评估乳腺癌患者骨转移的生化标志物。
Kaohsiung J Med Sci. 1999 Aug;15(8):452-60.
5
Prognostic value of the bone turnover markers in multiple myeloma.骨转换标志物在多发性骨髓瘤中的预后价值。
Exp Oncol. 2017 Mar;39(1):53-56.
6
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.无症状早期多发性骨髓瘤骨病的生化标志物。关于其在识别高危患者中作用的研究。
Haematologica. 2001 Apr;86(4):394-8.
7
[Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma].[多发性骨髓瘤患者骨髓中Dickkopf1的血浆浓度]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009 Sep;38(5):453-8. doi: 10.3785/j.issn.1008-9292.2009.05.004.
8
Response to bortezomib and activation of osteoblasts in multiple myeloma.硼替佐米的反应与多发性骨髓瘤中破骨细胞的活化
Clin Lymphoma Myeloma. 2006 Sep;7(2):109-14. doi: 10.3816/CLM.2006.n.047.
9
Analytical and clinical evaluation of a method to quantify bone alkaline phosphatase, a marker of osteoblastic activity.一种用于量化骨碱性磷酸酶(成骨细胞活性标志物)的方法的分析与临床评估。
Anticancer Res. 1997 Jul-Aug;17(4B):3167-70.
10
Comparison of assay of total and bone-specific alkaline phosphatase in the assessment of osteoblast activity in patients with metastatic bone disease.总碱性磷酸酶和骨特异性碱性磷酸酶检测在转移性骨病患者成骨细胞活性评估中的比较
Calcif Tissue Int. 1997 Nov;61(5):362-9. doi: 10.1007/s002239900349.

引用本文的文献

1
Retrospective cohort study on alkaline phosphatase and ICU mortality rate of multiple myeloma.多发性骨髓瘤碱性磷酸酶与重症监护病房死亡率的回顾性队列研究
Sci Rep. 2025 Aug 13;15(1):29623. doi: 10.1038/s41598-025-05458-3.
2
Clinical, oncological, and prognostic differences of patients with subsequent skeletal-related events in bone metastases.骨转移患者发生后续骨相关事件的临床、肿瘤学及预后差异。
Bone Joint Res. 2024 Sep 16;13(9):497-506. doi: 10.1302/2046-3758.139.BJR-2023-0372.R1.
3
Long-term Evolution of Hypophosphatemia and Osteomalacia in a Patient With Multiple Myeloma.一名多发性骨髓瘤患者低磷血症和骨软化症的长期演变
JCEM Case Rep. 2024 Jul 24;2(7):luae137. doi: 10.1210/jcemcr/luae137. eCollection 2024 Jul.
4
Recurrent central odontogenic fibroma in a patient with nevoid basal cell carcinoma syndrome: case report and in vitro analysis.复发性中枢性牙源性纤维瘤在神经嵴发育不全性基底细胞癌综合征患者中的表现:病例报告及体外分析。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2024 Jul;138(1):e18-e25. doi: 10.1016/j.oooo.2024.02.015. Epub 2024 Mar 6.
5
Validation of a Diagnostic Model to Differentiate Multiple Myeloma from Bone Metastasis.一种用于区分多发性骨髓瘤与骨转移的诊断模型的验证
Clin Epidemiol. 2023 Jul 24;15:881-890. doi: 10.2147/CLEP.S416028. eCollection 2023.
6
A novel and sensitive ratiometric fluorescent quantum dot-based biosensor for alkaline phosphatase detection in biological samples the inner-filter effect.一种用于生物样品中碱性磷酸酶检测的基于比率荧光量子点的新型灵敏生物传感器——内滤效应。
RSC Adv. 2023 Jan 16;13(4):2311-2317. doi: 10.1039/d2ra06956c. eCollection 2023 Jan 11.
7
Microporous structures on mineralized collagen mediate osteogenesis by modulating the osteo-immune response of macrophages.矿化胶原蛋白上的微孔结构通过调节巨噬细胞的骨免疫反应介导骨生成。
Front Bioeng Biotechnol. 2022 Aug 29;10:917655. doi: 10.3389/fbioe.2022.917655. eCollection 2022.
8
Modern markers for evaluating bone disease in multiple myeloma (Review).评估多发性骨髓瘤骨病的现代标志物(综述)
Exp Ther Med. 2021 Nov;22(5):1329. doi: 10.3892/etm.2021.10764. Epub 2021 Sep 20.
9
Development of a clinical diagnostic tool to differentiate multiple myeloma from bone metastasis in patients with destructive bone lesions (MM-BM DDx).开发一种临床诊断工具,以区分患有破坏性骨病变的患者中的多发性骨髓瘤和骨转移(MM-BM DDx)。
BMC Fam Pract. 2020 Oct 22;21(1):215. doi: 10.1186/s12875-020-01283-x.
10
Electrochemical Detection and Capillary Electrophoresis: Comparative Studies for Alkaline Phosphatase (ALP) Release from Living Cells.电化学检测与毛细管电泳:碱性磷酸酶(ALP)从活细胞释放的对比研究。
Biosensors (Basel). 2020 Aug 11;10(8):95. doi: 10.3390/bios10080095.

本文引用的文献

1
Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients.骨碱性磷酸酶作为胃癌患者骨转移的替代标志物。
BMC Cancer. 2016 Jul 4;16:385. doi: 10.1186/s12885-016-2415-x.
2
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
3
Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.碱性磷酸酶速度升高强烈预示去势抵抗性前列腺癌的总生存期和骨转移风险。
Urol Oncol. 2014 Aug;32(6):761-8. doi: 10.1016/j.urolonc.2014.03.024. Epub 2014 Jun 11.
4
Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.靶向多发性骨髓瘤细胞与骨髓瘤骨髓微环境的相互作用。
Int J Hematol. 2011 Oct;94(4):334-343. doi: 10.1007/s12185-011-0949-x. Epub 2011 Oct 18.
5
The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer.全身氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG PET/CT)、锝99m亚甲基二膦酸盐(Tc 99m MDP)骨闪烁显像及血清碱性磷酸酶在新诊断肺癌患者骨转移检测中的作用
J Korean Med Sci. 2009 Apr;24(2):275-80. doi: 10.3346/jkms.2009.24.2.275. Epub 2009 Apr 21.
6
Myeloma bone disease: recent advances in biology, diagnosis, and treatment.骨髓瘤骨病:生物学、诊断及治疗的最新进展
Oncologist. 2009 Mar;14(3):276-83. doi: 10.1634/theoncologist.2009-0003. Epub 2009 Mar 13.
7
Pathogenesis of myeloma bone disease.骨髓瘤骨病的发病机制。
Leukemia. 2009 Mar;23(3):435-41. doi: 10.1038/leu.2008.336. Epub 2008 Nov 27.
8
Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma.PINP、骨碱性磷酸酶、CTX-I和YKL-40在转移性前列腺癌患者中的预后价值。
Prostate. 2006 Apr 1;66(5):503-13. doi: 10.1002/pros.20311.
9
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.骨吸收和形成标志物在接受双膦酸盐唑来膦酸治疗的骨转移癌患者中的预测价值。
J Clin Oncol. 2005 Aug 1;23(22):4925-35. doi: 10.1200/JCO.2005.06.091. Epub 2005 Jun 27.
10
Myeloma bone disease: pathophysiology and management.骨髓瘤骨病:病理生理学与管理
Ann Oncol. 2005 Aug;16(8):1223-31. doi: 10.1093/annonc/mdi235. Epub 2005 May 31.